Cargando…
Timing of Intensive Immunosuppression Impacts Risk of Transgene Antibodies after AAV Gene Therapy in Nonhuman Primates
Adeno-associated virus (AAV) vector gene therapy is a promising treatment for a variety of genetic diseases, including hemophilia. Systemic administration of AAV vectors is associated with a cytotoxic immune response triggered against AAV capsid proteins, which if untreated can result in loss of tra...
Autores principales: | Samelson-Jones, Benjamin J., Finn, Jonathan D., Favaro, Patricia, Wright, J. Fraser, Arruda, Valder R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256432/ https://www.ncbi.nlm.nih.gov/pubmed/32490034 http://dx.doi.org/10.1016/j.omtm.2020.05.001 |
Ejemplares similares
-
Translational Potential of Immune Tolerance Induction by AAV Liver-Directed Factor VIII Gene Therapy for Hemophilia A
por: Samelson-Jones, Benjamin J., et al.
Publicado: (2020) -
Widespread AAV1- and AAV2-mediated transgene expression in the nonhuman primate brain: implications for Huntington’s disease
por: Hadaczek, Piotr, et al.
Publicado: (2016) -
Axonal transport of AAV9 in nonhuman primate brain
por: Green, Foad, et al.
Publicado: (2016) -
Transgenic nonhuman primates for neurodegenerative diseases
por: Chan, Anthony WS
Publicado: (2004) -
AAV9 Targets Cone Photoreceptors in the Nonhuman Primate Retina
por: Vandenberghe, Luk H., et al.
Publicado: (2013)